Free tool
FAERS Monitor: Ocuflox
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019921 or its brand name (Ocuflox, Ofloxacin). Reports on generic versions are filed under their own applications.
Reports
7,237
Serious
5,537
77% of reports
Hospitalization
2,690
Death reported
615
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain366
- drug ineffective349
- off label use318
- headache291
- pain274
- fatigue272
- arthralgia260
- nausea257
- diarrhoea252
- acute kidney injury248
- anxiety215
- pyrexia213
- renal failure213
- dyspnoea211
- chronic kidney disease194
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 131 |
| 2005 | 103 |
| 2006 | 98 |
| 2007 | 96 |
| 2008 | 111 |
| 2009 | 141 |
| 2010 | 93 |
| 2011 | 203 |
| 2012 | 242 |
| 2013 | 151 |
| 2014 | 154 |
| 2015 | 218 |
| 2016 | 289 |
| 2017 | 375 |
| 2018 | 531 |
| 2019 | 594 |
| 2020 | 546 |
| 2021 | 582 |
| 2022 | 617 |
| 2023 | 640 |
| 2024 | 508 |
| 2025 | 499 |
| 2026 | 314 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,922 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| eye painSignal | 366 | 19.0 | 17.2 | 6,189 |
| chronic kidney diseaseSignal | 194 | 7.4 | 6.5 | 1,076 |
| acute kidney injurySignal | 248 | 4.7 | 4.2 | 727 |
| renal failureSignal | 213 | 4.7 | 4.1 | 613 |
| anxietySignal | 215 | 2.2 | 1.9 | 141 |
| arthralgia | 260 | 1.8 | 1.6 | 97 |
| pyrexia | 213 | 1.8 | 1.6 | 75 |
| headache | 291 | 1.3 | 1.2 | 27 |
| pain | 274 | 1.3 | 1.2 | 19 |
| diarrhoea | 252 | 1.1 | 1.0 | 4 |
| dyspnoea | 211 | 1.1 | 0.9 | 1 |
| off label use | 318 | 1.1 | 0.9 | 1 |
| fatigue | 272 | 1.0 | 0.9 | 0 |
| nausea | 257 | 0.9 | 0.8 | 1 |
| drug ineffective | 349 | 0.8 | 0.7 | 25 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.